28 May 2022
Bristol-Myers Squibb Company: A String Of FDA Approvals & Other Drivers, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (05/22)
Bristol-Myers Squibb Company had a strong start to 2022 with the U.S. FDA having approved the Camzyos or mavacanten, a first-class medicine for symptomatic obstructive HCM disease. The company also received approval for Opdualag to treat unresectable or metastatic melanoma and thy have started a pivotal study for colorectal cancer.. In March, U.S. FDA also approved Opdivo as the foremost I-O agent for treating the early stages of lung cancer whereas in Europe, Breyanzi has received regulatory ap ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bristol-Myers Squibb Company: A String Of FDA Approvals & Other Drivers, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (05/22)
Bristol-Myers Squibb Company (BMY:NYS) | 0 0 0.0%
- Published:
28 May 2022 -
Author:
Ishan Majumdar -
Pages:
26
Bristol-Myers Squibb Company had a strong start to 2022 with the U.S. FDA having approved the Camzyos or mavacanten, a first-class medicine for symptomatic obstructive HCM disease. The company also received approval for Opdualag to treat unresectable or metastatic melanoma and thy have started a pivotal study for colorectal cancer.. In March, U.S. FDA also approved Opdivo as the foremost I-O agent for treating the early stages of lung cancer whereas in Europe, Breyanzi has received regulatory ap ....